Graveoline analogs exhibiting selective acetylcholinesterase inhibitory activity as potential lead compounds for the treatment of Alzheimer's disease

Molecules

Volumn 21, Issue 2, 2016, Pages

  Li, Zeng ^a   Mu, Chaoyu ^a,b   Wang, Bin ^c   Jin, Juan ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Huaibei Miner's General Hospital   (China)

^c XIANGNAN UNIVERSITY   (China)

Author keywords

Acetylcholinesterase (AChE); Butyrylcholine esterase (BuChE); Graveoline analogs; Mechanism; Structure function relationships (SARs)

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; GRAVEOLINE; METHOXSALEN;

ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; BINDING SITE; CELL LINE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; MOLECULAR DOCKING; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; BINDING SITES; BUTYRYLCHOLINESTERASE; CELL LINE; CELL PROLIFERATION; CHOLINESTERASE INHIBITORS; HUMANS; METHOXSALEN; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84962868714     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21020132     Document Type: Article

References (23)

1. Amemori, T.; Jendelova, P.; Ruzicka, J.; Urdzikova, L.M.; Sykova, E. Alzheimer's disease: Mechanism and approach to cell therapy. Int. J. Mol. Sci. 2015, 16, 26417-26451. [CrossRef] [PubMed]
2. Saiz-Sanchez, D.; Flores-Cuadrado, A.; Ubeda-Bañon, I.; de la Rosa-Prieto, C.; Martinez-Marcos, A. Interneurons in the human olfactory system in Alzheimer's disease. Exp. Neurol. 2015, 276, 13-21. [CrossRef] [PubMed]
3. Klimova, B.; Maresova, P.; Valis, M.; Hort, J.; Kuca, K. Alzheimer's disease and language impairments: social intervention and medical treatment. Clin. Interv. Aging 2015, 10, 1401-1407. [PubMed]
4. Sadigh-Eteghad, S.; Sabermarouf, B.; Majdi, A.; Talebi, M.; Farhoudi, M.; Mahmoudi, J. Amyloid-β: A crucial factor in Alzheimer's disease. Med. Princ. Pract. 2015, 24, 1-10. [CrossRef] [PubMed]
5. Henderson, Z. Responses of basal forebrain cholinergic neurons to damage in the adult brain. Prog. Neurobiol. 1996, 48, 219-254. [CrossRef]
6. Selkoe, D.J. Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 2001, 81, 741-766. [CrossRef] [PubMed]
7. Kandemirli, F.; Saraçoglu, M.; Kovalishyn, V. Human acetylcholinesterase inhibitors: Electronic-topological and neural network approaches to the structure-activity relationships study. Mini Rev. Med. Chem. 2005, 5, 479-487. [CrossRef] [PubMed]
8. De Ferrari, G.V.; Canales, M.A.; Shin, I.; Weiner, L.M.; Silman, I.; Inestrosa, N.C. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry 2001, 40, 10447-10457. [CrossRef] [PubMed]
9. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. β-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem. Pharmacol. 2003, 65, 407-416. [CrossRef]
10. Mesulam, M.M.; Asuncion Morán, M. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann. Neurol. 1987, 22, 223-228. [CrossRef] [PubMed]
11. Cummings, J.L.; Doody, R.; Clark, C. Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology 2007, 69, 1622-1634. [CrossRef] [PubMed]
12. Pacheco, G.; Palacios-Esquivel, R.; Moss, D.E. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: Selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J. Pharmacol. Exp. Ther. 1995, 274, 767-770. [PubMed]
13. Liston, D.R.; Nielsen, J.A.; Villalobos, A.; Chapin, D.; Jones, S.B.; Hubbard, S.T.; Shalaby, I.A.; Ramirez, A.; Nason, D. Pharmacology of selective acetylcholinesterase inhibitors: Implications for use in Alzheimer's disease. Eur. J. Pharmacol. 2004, 486, 9-17. [CrossRef] [PubMed]
14. Kuhl, D.E.; Koeppe, R.A.; Snyder, S.E.; Minoshima, S.; Frey, K.A.; Kilbourn, M.R. In vivobutyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann. Neurol. 2006, 59, 13-20. [CrossRef] [PubMed]
15. El Sayed, K.; Al-Said, M.S.; El-Feraly, F.S.; Ross, S.A. New quinoline alkaloids from Ruta chalepensis. J. Nat. Prod. 2000, 63, 995-997. [CrossRef] [PubMed]
16. Hale, A.L.; Meepagala, K.M.; Oliva, A.; Aliotta, G.; Duke, S.O. Phytotoxins from the leaves of Ruta graveolens. J. Agric. Food Chem. 2004, 52, 3345-3349. [CrossRef] [PubMed]
17. Ghosh, S.; Bishayee, K.; Khuda-Bukhsh, A.R. Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: A novel apoptosis-independent autophagic signaling pathway. Phytother. Res. 2014, 28, 1153-1162. [CrossRef] [PubMed]
18. Yu, Q.; Zhu, X.; Holloway, H.W.; Whittaker, N.F.; Brossi, A.; Greig, N.H. Anticholinesterase activity of compounds related to geneserine tautomers. N-oxides and 1,2-oxazines. J. Med. Chem. 2002, 45, 3684-3691. [PubMed]
19. Takeuchi, Y.; Shibata, T.; Suzuki, E.; Iimura, Y.; Kosasa, T.; Yamanishi, Y.; Sugimoto, H. 1-Benzyl-4-[(5,6-dimethoxy-2-fluor-1-indanon)-2-y1]methyl Piperidine. European Patent WO 02/20482 A1, 14 March 2012.
20. Martineza, A.; Fernandeza, E.; Castroa, A.; Condea, S.; Rodriguez-Francoa, L.; Banosb, J.E.; Badiab, A. N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. Eur. J. Med. Chem. 2000, 35, 913-922. [CrossRef]
21. Ellman, G.L.; Courtney, K.D.; Andres, V.R., Jr.; Featherstone, M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95. [CrossRef]
22. Wang, B.; Mai, Y.C.; Li, Y.; Hou, J.Q.; Huang, S.L.; Ou, T.M.; Tan, J.H.; An, L.K.; Li, D.; Gu, L.Q.; et al. Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur. J. Med. Chem. 2010, 45, 1415-1423. [CrossRef] [PubMed]
23. Smith, R.A.; Laura, P.; Carrie, W.; Meghan, L.; Jared, W. Comparison of motility, recovery, and methyl-thiazolyl-tetrazolium reduction assays for use in screening plant products for anthelmintic activity. Parasitol. Res. 2009, 105, 1339-1343. [CrossRef] [PubMed]